Tulsi used in metabolic disorder

Tulsi, also known as holy basil, is indigenous to the Indian continent and highly revered for its medicinal uses within the Ayurvedic and Siddha medical systems. Many in vitro, animal and human studies attest to tulsi having multiple therapeutic actions including adaptogenic, antimicrobial, anti-inflammatory, cardioprotective, and immunomodulatory effects.

Tulsi in Hindi or Tulasi in Sanskrit (holy basil in English) is a highly revered culinary and medicinal aromatic herb from the family Lamiaceae that is indigenous to the Indian subcontinent and been used within Ayurvedic medicine more than 3000 years.

Three types of tulsi are commonly described. Ocimum tenuiflorum (or Ocimum sanctum L.) includes 2 botanically and phytochemically distinct cultivars that include Rama or Sri tulsi (green leaves) and Krishna or Shyama tulsi (purplish leaves). while Ocimum gratissimum is a third type of tulsi known as Vana or wild/forest tulsi (dark green leaves)



Metabolic Disorders

Seventeen clinical trials reported on metabolic conditions with ten studies reporting on type 2 diabetes or metabolic syndrome with measures of blood glucose, lipids, and blood pressure, yet only one study reported on the clinical symptoms associated with type 2 diabetes such as polydipsia, polyphagia, polyuria, sweating, fatigue, burning feet, itching, and headache.

Immunomodulation and Inflammation

Enhanced immune response was reported in five clinical studies. A small randomized double-blind, and placebo-controlled trial found increased immune response with increased Natural Killer (NK) and T-helper cells in healthy adult participants compared to placebo volunteers after 4 weeks of 300 mg or ethanolic tulsi leaf extract daily taken before food .

Another 2-week controlled randomized study in which young adult volunteers were provided with nutrition bars fortified with 1 g of ethanolic tulsi leaf extract found that compared to control participants, the intervention group had significantly improved VO2 max, less fatigue, reduced Creatine Kinase, and improved immune response to viral infection as indicated by reduced load of human herpesvirus 6 in saliva .

 Neurocognitive Effect

The four studies that reported on neurocognitive effects all showed significant improvements in mood and/or cognitive function regardless of age, gender, formulation, dose, or quality of the study. Cognition function was assessed in a randomized, placebo-controlled, clinical trial that demonstrated an improvement in cognitive flexibility, short-term memory, and attention in 40 healthy young adults . following treatment with 300 mg daily tulsi for 4 weeks. However, the cognitive effects of tulsi were only significant after the first two weeks compared to the placebo, with no significant difference found in stress levels. This is in contrast to three clinical studies that reported significant reduction in anxiety and stress levels with higher doses of tulsi given over a longer time period.


Comments

Post a Comment

Popular posts from this blog

article review on tocilizumab production

Tocilizumab (Actemra) is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor, which is involved in the inflammatory response. It is used to treat rheumatoid arthritis, systemic juvenile idiopathic arthritis and other inflammatory conditions. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. One research article "Development of an efficient and scalable fed-batch culture process for the production of tocilizumab in Chinese hamster ovary cells" by Li et al. (2019) aimed to optimize the production of tocilizumab using a fed-batch cultivation system in CHO cells. The study aimed to improve the yield and quality of the protein, and to develop a process that can be easily scaled up for industrial production. The results of the study showed that the yield of tocilizumab was significantly improved by optimizing the culture conditions, such as the temperature, pH, and dissolved oxygen, as well as by using a specific
Read more

MOA OF AMINOGLYCOSIDE ANTIBIOTICS

Image
MOA                  of   Aminoglycoside             Antibiotics Aminoglycosides exert their bactericidal effect by inhibiting protein synthesis in bacteria and compromising the structure of the bacterial cell wall . Aminoglycoside Antibiotics Aminoglycoside antibiotics are used to treat serious infections caused by gram-negative bacteria . Some commonly used aminoglycosides include: amikacin (Amikin®); apramycin; capreomycin; gentamicin (Garamycin®); kanamycin (Kantrex®); neomycin (Mycifradin®); netilmicin (Netromycin®); paromomycin (Humatin®); streptomycin; tobramycin (TOBI Solution®, TobraDex®, Nebcin®) Mode of Action Although aminoglycosides stop bacteria from making proteins, it is uncertain whether this is the action that results in bacterial cell death.     Disruption of Protein Synthesis A minoglyco s i d e s b i n d to the b a c t er i al 3 0 S r i b o s o mal s ubunit. R i b o s om e s are the p ro t e i n
Read more

article review on adalimumab production

Adalimumab is a recombinant human monoclonal antibody that is used to treat a variety of inflammatory diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. A research article "Development of a high-titer, high-density fed-batch process for the production of adalimumab in CHO cells" by Chen et al. (2018) aimed to improve the production of adalimumab by developing a high-titer and high-density fed-batch process. The study used a CHO cell line that had been modified to express the adalimumab gene. The cells were grown in a culture medium containing glucose, amino acids, and a proprietary feed supplement, and the culture conditions were optimized to achieve high yields of the protein. The results of the study showed that a high yield of adalimumab (over 2g/L) was achieved using the fed-batch cultivation system. The study also found that the specific productivity of th
Read more